These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Somatostatin analogues do not affect calcium metabolism in patients with acromegaly and primary hyperparathyroidism [corrected] due to MEN 1-like syndrome. Bogazzi F, Lombardi M, Russo D, Sardella C, Raggi F, Brogioni S, Cetani F, Ceccarelli C, Mariani G, Basolo F, Martino E. Horm Metab Res; 2011 Feb; 43(2):126-9. PubMed ID: 20972944 [Abstract] [Full Text] [Related]
3. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A, Multidisciplinary Group for Neuroendocrine Tumors of Naples. Clin Endocrinol (Oxf); 2014 Jun; 80(6):850-5. PubMed ID: 24443791 [Abstract] [Full Text] [Related]
4. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD. Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503 [Abstract] [Full Text] [Related]
6. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A. Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106 [Abstract] [Full Text] [Related]
7. [Octreotide therapy in multiple endocrine neoplasia type-1]. Valkusz Z, Gáspár L, Julesz J, Pávics L. Orv Hetil; 2002 May 12; 143(19 Suppl):1078-81. PubMed ID: 12063865 [Abstract] [Full Text] [Related]
8. Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism. Yip L, Ogilvie JB, Challinor SM, Salata RA, Thull DL, Yim JH, Carty SE. Surgery; 2008 Dec 12; 144(6):1002-6; discussion 1006-7. PubMed ID: 19041010 [Abstract] [Full Text] [Related]
9. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Aliment Pharmacol Ther; 2000 May 12; 14(5):557-60. PubMed ID: 10792118 [Abstract] [Full Text] [Related]
19. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC. Clin Endocrinol (Oxf); 2009 Apr 12; 70(4):533-8. PubMed ID: 18782355 [Abstract] [Full Text] [Related]